Release Date: 20/03/12 10:03 Summary: KRE to pursue complementary growth opportunities Price Sensitive: Yes Download Document 249.17KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%